Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Eita Sasaki, Hideki Asanuma
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Human immune responses elicited by an intranasal inactivated H5 influenza vaccine
10.1111/1348-0421.12775 · 2020
Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract
10.4049/jimmunol.173.3.1978 · 2004
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
10.1126/scitranslmed.abh0755 · 2021
Mucosal vaccines—fortifying the frontiers
10.1038/s41577-021-00583-2 · 2022
Next-generation influenza vaccines: opportunities and challenges
10.1038/s41573-019-0056-x · 2020
Innovative mucosal vaccine formulations against influenza A virus infections
10.3389/fimmu.2019.01605 · 2019
Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling
10.1371/journal.ppat.1000138 · 2008
Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs
10.1111/j.1750-2659.2008.00038.x · 2008
Traditional and new influenza vaccines
10.1128/cmr.00097-12 · 2013
Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature
10.2165/00044011-199815010-00001 · 1998
Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults
10.4161/hv.25458 · 2013
A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children
10.1093/infdis/136.5.623 · 1977
Molecular mechanisms of necroptosis: an ordered cellular explosion
10.1038/nrm2970 · 2010
Programmed necrosis in the cross talk of cell death and inflammation
10.1146/annurev-immunol-032414-112248 · 2015
Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes
10.1126/scitranslmed.3000759 · 2010
Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells
10.1084/jem.20071087 · 2008
Nasal alum-adjuvanted vaccine promotes IL-33 release from alveolar epithelial cells that elicits IgA production via type 2 immune responses
10.1371/journal.ppat.1009890 · 2021
Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode–infected mice
10.1073/pnas.1201042109 · 2012
DNA released from dying host cells mediates aluminum adjuvant activity
10.1038/nm.2403 · 2011
Inhaled fine particles induce alveolar macrophage death and interleukin-1α release to promote allergic sensitization
10.1016/j.immuni.2016.11.010 · 2016
Influenza A whole-virion vaccine induces a rapid reduction of peripheral blood leukocytes by apoptosis
10.1016/j.vaccine.2013.02.016 · 2013
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics
10.1038/bjc.1972.33 · 1972
Death receptors: signaling and modulation
10.1126/science.281.5381.1305 · 1998
Apoptosis signaling by death receptors
10.1046/j.1432-1327.1998.2540439.x · 1998
Molecular mechanisms of caspase regulation during apoptosis
10.1038/nrm1496 · 2004
Apoptosis: controlled demolition at the cellular level
10.1038/nrm2312 · 2008
Plasmacytoid dendritic cells in immunity
10.1038/ni1141 · 2004
IL-5-producing Group 2 innate lymphoid cells promote T cell-independent IgA production in cooperation with eosinophils
10.1093/intimm/dxae070 · 2025
The polymeric immunoglobulin receptor (secretory component) in a human intestinal epithelial cell line is up-regulated by interleukin-1
10.1046/j.1365-2567.1997.00341.x · 1997
IL-1beta and TNF-alpha induce increased expression of CCL28 by airway epithelial cells via an NFkappaB-dependent pathway
10.1016/j.cellimm.2006.02.003 · 2005
CCL28 controls immunoglobulin (Ig)A plasma cell accumulation in the lactating mammary gland and IgA antibody transfer to the neonate
10.1084/jem.20041069 · 2004
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
10.1038/nature00858 · 2002
Induction of TNF receptor I–mediated apoptosis via two sequential signaling complexes
10.1016/s0092-8674(03)00521-x · 2003
Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland
10.1056/nejmoa030595 · 2004
Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin
10.1371/journal.pone.0006999 · 2009
Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
10.1056/nejmoa2034577 · 2020
IL-33 regulates the IgA-microbiota axis to restrain IL-1α–dependent colitis and tumorigenesis
10.1172/jci88625 · 2016
Bacteria-induced group 2 innate lymphoid cells in the stomach provide immune protection through induction of IgA
10.1016/j.immuni.2020.03.002 · 2020
Lipid nanoparticles for mRNA delivery
10.1038/s41578-021-00358-0 · 2021
Intranasal drug delivery: the interaction between nanoparticles and the nose-to-brain pathway
10.1016/j.addr.2024.115196 · 2024
Induction of mucosal immunity by intranasal application of vaccines: specific homing of antibody-secreting cells to the nasal-associated lymphoid tissue and related mucosal sites
10.1128/iai.61.1.314-322.1993 · doi-reference
Recent progress in mucosal vaccine development: potential and limitations
10.1038/nri3251 · doi-reference
Interleukin 1α and the inflammatory process
10.1038/ni.3503 · doi-reference